1. Home
  2. LQDA vs HAFN Comparison

LQDA vs HAFN Comparison

Compare LQDA & HAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • HAFN
  • Stock Information
  • Founded
  • LQDA 2004
  • HAFN 2012
  • Country
  • LQDA United States
  • HAFN Singapore
  • Employees
  • LQDA N/A
  • HAFN N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • HAFN
  • Sector
  • LQDA Health Care
  • HAFN
  • Exchange
  • LQDA Nasdaq
  • HAFN Nasdaq
  • Market Cap
  • LQDA 2.5B
  • HAFN 2.7B
  • IPO Year
  • LQDA 2018
  • HAFN N/A
  • Fundamental
  • Price
  • LQDA $25.00
  • HAFN $6.34
  • Analyst Decision
  • LQDA Strong Buy
  • HAFN Strong Buy
  • Analyst Count
  • LQDA 9
  • HAFN 1
  • Target Price
  • LQDA $32.11
  • HAFN $6.50
  • AVG Volume (30 Days)
  • LQDA 2.2M
  • HAFN 1.3M
  • Earning Date
  • LQDA 11-12-2025
  • HAFN 08-27-2025
  • Dividend Yield
  • LQDA N/A
  • HAFN 9.90%
  • EPS Growth
  • LQDA N/A
  • HAFN N/A
  • EPS
  • LQDA N/A
  • HAFN 0.84
  • Revenue
  • LQDA $19,322,000.00
  • HAFN $2,354,657,000.00
  • Revenue This Year
  • LQDA $405.58
  • HAFN N/A
  • Revenue Next Year
  • LQDA $373.93
  • HAFN N/A
  • P/E Ratio
  • LQDA N/A
  • HAFN $7.55
  • Revenue Growth
  • LQDA 30.20
  • HAFN N/A
  • 52 Week Low
  • LQDA $9.68
  • HAFN $3.61
  • 52 Week High
  • LQDA $29.94
  • HAFN $7.84
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 45.82
  • HAFN 63.70
  • Support Level
  • LQDA $25.34
  • HAFN $5.98
  • Resistance Level
  • LQDA $28.00
  • HAFN $6.43
  • Average True Range (ATR)
  • LQDA 1.32
  • HAFN 0.14
  • MACD
  • LQDA -0.70
  • HAFN 0.00
  • Stochastic Oscillator
  • LQDA 0.50
  • HAFN 82.00

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About HAFN Hafnia Limited Common Shares

Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.

Share on Social Networks: